CAPTRUST Financial Advisors
UNCY icon

CAPTRUST Financial Advisors’s Unicycive Therapeutics UNCY Stock Holding History

CAPTRUST Financial Advisors’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,880
Closed -$7.67K – 2402
2024
Q3 		$7.67K Hold
1,880
– – ﹤0.01% 2278
2024
Q2 		$9.42K Hold
1,880
– – ﹤0.01% 2188
2024
Q1 		$25.9K Hold
1,880
– – ﹤0.01% 2109
2023
Q4 		$16.3K Hold
1,880
– – ﹤0.01% 2625
2023
Q3 		$16.2K Hold
1,880
– – ﹤0.01% 2529
2023
Q2 		$24.1K Hold
1,880
– – ﹤0.01% 2458
2023
Q1 		$39.5K Buy
+1,880
New +$18.7K ﹤0.01% 2225
2022
Q4 		– Sell
-1,880
Closed -$11K – 2189
2022
Q3 		$11K Buy
+1,880
New +$13.8K ﹤0.01% 2030

Other funds holding UNCY

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM

CAPTRUST Financial Advisors's UNCY Position: Q4 2024 in Review

CAPTRUST Financial Advisors sold out of Unicycive Therapeutics (UNCY) in Q4 2024, closing a stake of 1,880 shares — an estimated $7.67K sold.

CAPTRUST Financial Advisors first reported a position in UNCY in Q3 2022 and held it in 8 quarters. The position peaked at $39.5K in Q1 2023. 30 funds tracked by Wall St. Rank hold UNCY as of Q4 2024.

  • CAPTRUST Financial Advisors reported no remaining Unicycive Therapeutics position as of Q4 2024 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 1,880 Unicycive Therapeutics shares in Q4 2024, an estimated $7.67K.
  • CAPTRUST Financial Advisors first reported a position in Unicycive Therapeutics in Q3 2022 and held it in 8 quarters.
  • CAPTRUST Financial Advisors's Unicycive Therapeutics position peaked at $39.5K in Q1 2023.
  • 30 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q4 2024.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.